8-K: Current report filing
Published on August 9, 2002
=====================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): August 7, 2002
Commonwealth Biotechnologies, Inc.
(Exact name of registrant as specified in its charter)
Virginia 001-13467 56-1641133
-------- --------- ----------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)
Registrant's telephone number, including area code: (804) 648-3820
=====================================================================
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANICIAL INFORMATION AND EXHIBITS.
(a) Financial statements of businesses acquired.
Not applicable.
(b) Pro forma financial information.
Not applicable.
(c) Exhibits.
99.1 Press Release, dated August 7, 2002, relating to the
Company's financial results for the second fiscal quarter of 2002.
-2-
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC.
Dated: August 8, 2002 By:
/s/ Robert B. Harris, Ph.D.
---------------------------
Robert B. Harris, Ph.D.
President and Chief Executive Officer
-3-
INDEX TO EXHIBITS
99.1 Press Release, dated August 7, 2002, relating to the Company's financial
results for the second fiscal quarter of 2002.
-4-